Nuvalent

#News for #investors and #media: We have entered an agreement to acquire clinical-stage precision oncology company Nuvalent, Inc., bringing in multiple lung cancer assets to our existing oncology portfolio. Find out more: gsk.to/4ooHOjy

That’s a wrap on the 2026 @ASCO Annual Meeting. The #NuCrew had a great time connecting with the #oncology community and presenting clinical updates from our #ALK+ #NSCLC and #ROS1+ programs. Thanks to all who joined for our oral presentation and stopped by our poster. #ASCO26

Today on #NationalCancerSurvivorsDay, we recognize the strength and resilience of all #CancerSurvivors, including those facing the unique challenges of ALK+ and ROS1+ #LungCancer. To patients, caregivers, and loved ones: we stand with you.💪 #ALKPositive #ROS1Positive

Proud to stand with @ALKPositiveinc & the ALK #LungCancer community for #ALKAwarenessMonth!🎗️#FuelTheCure honors the patients, researchers & advocates driving progress. Together, we fuel hope, research & innovation. #APAM26

Additionally, we are pleased to welcome Georg Pirmin Meyer, M.D. as Chief International Officer to lead our international expansion strategy. Learn more here: investors.nuvalent.com/2026-05-27-Nuv…

We are excited to share that the FDA has accepted for filing with Priority Review our NDA for neladalkib, our investigational ALK-selective inhibitor in TKI pre-treated advanced ALK-positive #NSCLC with a PDUFA date of November 27, 2026.

Join us at the 2026 @ASCO Annual Meeting, where we’ll present clinical updates from our #ALK+ #NSCLC and ROS1+ programs. Learn more here. investors.nuvalent.com/2026-05-21-Nuv… #ASCO26

We recognize the emotional weight of a #LungCancer journey. This #MentalHealthAwareness month, find strength through support. Connect with patient advocacy groups like @ALKPositiveinc and @ros1cancer, where patients & caregivers come together to share and uplift one another.

This morning, we reported our Q1 2026 financial results, along with recent pipeline and business progress and anticipated milestones. Learn more here. investors.nuvalent.com/2026-05-07-Nuv…

The #NuCrew had a great time @AACR 2026 engaging with the #oncology community and presenting new data for our #ROS1+ #NSCLC program. Thanks to all who stopped by our posters! #AACR26

Join us in welcoming Riley, Ashley, Kyle, and Tiffany to the #NuCrew! 🎉 We’re excited to have them on board!

Join us at the 2026 @ASCO Annual Meeting in Chicago where we'll present clinical updates from our #ALK+ #NSCLC and #ROS1+ programs. Learn more: investors.nuvalent.com/2026-04-21-Nuv… #ASCO26

This week at @AACR 2026, we're pleased to share new clinical and preclinical data for our #ROS1 + #NSCLC program. Learn more here. #AACR26" target="_blank" rel="nofollow noopener">investors.nuvalent.com/2026-04-17-New…

During #CancerPrevention and #EarlyDetection Month, we’re honoring the stories of patients like Luna and Brandi. Through biomarker testing, they discovered important answers that helped guide their treatment journeys. Learn about ROS1 & ALK+ NSCLC & more→elevatelungcancercare.com.

We are pleased to announce the submission of our New Drug Application to the FDA for investigational candidate neladalkib in TKI pre-treated advanced ALK-positive NSCLC. Learn more: investors.nuvalent.com/2026-04-07-Nuv…

April is #CancerPrevention & #EarlyDetection Month. 🎗️We’re raising awareness, alongside @ros1cancer and @ALKPositiveinc, about the importance of routine screenings and biomarker testing. Learn about biomarker testing and more → elevatelungcancercare.com.

Join us at the @AACR 2026 Annual Meeting in San Diego where we'll present new clinical and preclinical data for our ROS1+ NSCLC program. Learn more: investors.nuvalent.com/2026-03-17-Nuv…  #AACR26

Today, we outlined pipeline progress, reiterated key anticipated milestones, and reported Q4 & full year 2025 financial results. Our CEO Jim Porter shares what’s ahead as we work to create precisely targeted therapies for people living with #cancer. $NUVL investors.nuvalent.com/2026-02-26-Nuv…

We’re proud to support the @IASLC 2026 Targeted Therapies of Lung Cancer Meeting, which brings together global experts in #LungCancer research and care.

The breakthroughs of today are built on the courage of yesterday. This International Day of Women & Girls in Science, we’re honored to recognize the pioneers who transformed our industry and the incredible women across Nuvalent who continue to push science forward. #WomenInSTEM